These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32191306)

  • 21. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
    Ray N; Hwang C; Healy MD; Whitcomb J; Lataillade M; Wind-Rotolo M; Krystal M; Hanna GJ
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):7-15. PubMed ID: 23614999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
    Kato K; Sato H; Takebe Y
    J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding.
    Wang HG; Williams RE; Lin PF
    Curr Pharm Des; 2004; 10(15):1785-93. PubMed ID: 15180540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.
    De Wolf F; Hogervorst E; Goudsmit J; Fenyö EM; Rübsamen-Waigmann H; Holmes H; Galvao-Castro B; Karita E; Wasi C; Sempala SD
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1387-400. PubMed ID: 7888192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different HIV-1 env frames: gp120 and ASP (antisense protein) biosynthesis, and theirs co-variation tropic amino acid signatures in X4- and R5-viruses.
    Dimonte S
    J Med Virol; 2017 Jan; 89(1):112-122. PubMed ID: 27328810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes.
    Yamaguchi-Kabata Y; Gojobori T
    J Virol; 2000 May; 74(9):4335-50. PubMed ID: 10756049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
    Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The molecular epidemiology and drug resistance determination of HIV type 1 subtype B infection in Barbados.
    Gittens MV; Roth WW; Roach T; Stringer HG; Pieniazek D; Bond VC; Levett PN
    AIDS Res Hum Retroviruses; 2003 Apr; 19(4):313-9. PubMed ID: 12816080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlated mutations at gp120 positions 322 and 440: implications for gp120 structure.
    Rosen O; Samson AO; Anglister J
    Proteins; 2008 May; 71(3):1066-70. PubMed ID: 18275085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.
    Pollakis G; Abebe A; Kliphuis A; Chalaby MI; Bakker M; Mengistu Y; Brouwer M; Goudsmit J; Schuitemaker H; Paxton WA
    J Virol; 2004 Mar; 78(6):2841-52. PubMed ID: 14990703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
    Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
    Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures.
    Antell GC; Dampier W; Aiamkitsumrit B; Nonnemacher MR; Jacobson JM; Pirrone V; Zhong W; Kercher K; Passic S; Williams JW; Schwartz G; Hershberg U; Krebs FC; Wigdahl B
    Retrovirology; 2016 May; 13(1):32. PubMed ID: 27143130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linkage of amino acid variation and evolution of human immunodeficiency virus type 1 gp120 envelope glycoprotein (subtype B) with usage of the second receptor.
    Yamaguchi-Kabata Y; Yamashita M; Ohkura S; Hayami M; Miura T
    J Mol Evol; 2004 Mar; 58(3):333-40. PubMed ID: 15045488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.